CytomX Therapeutics (CTMX) Current Deferred Revenue (2014 - 2026)

CytomX Therapeutics has reported Current Deferred Revenue for 13 years, with the latest figure at $17.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 63.84% year-over-year to $17.9 million; the trailing twelve-month figure through Mar 2026 stood at $17.9 million (down 63.84% YoY), and the FY2025 full-year result was $26.9 million, down 71.43% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $17.9 million, down from $26.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $301.3 million in Q4 2022, with the low at $4.0 million in Q1 2023.
• Historically, Current Deferred Revenue has averaged $147.9 million across 5 years, with a median of $160.5 million in 2024.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue tumbled 98.55% — and 2024, when it surged 4484.28%.
• CytomX Therapeutics' Current Deferred Revenue stood at $301.3 million in 2022, then retreated by 29.54% to $212.3 million in 2023, then plunged by 55.7% to $94.1 million in 2024, then plunged by 71.43% to $26.9 million in 2025, then sank by 33.49% to $17.9 million in 2026.
• The last three Current Deferred Revenue figures came in at $17.9 million (Q1 2026), $26.9 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.